[Skip to content]

European Parkinson's Disease Association
Search our Site



Medication research papers

  • Neurology Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson diseaseDiscontinuation was most frequently caused by device- or infusion-related adverse events. Ten patients of the remaining 31 discontinued DLI. There were 2 main causes of withdrawal: stoma infection (4 patients), and worsening of dyskinesias not manageable with infusion reduction (3 patients). In most patients, discontinuations occurred during the first year after implant. Risk of discontinuation was related to age at implant, but no other demographic or clinical variables. 21 April 2015
  • Parkinson's Disease Pharmacokinetic Study and Optimal Formulation of New Anti-Parkinson Natural Compound Schisantherin AThis study provides a successful example of advanced delivery system for improving the bioavailability of potential central nervous system (CNS) drug candidate with poor solubility. This novel approach could be an effective alternative solution to overcome the shortcomings of conventional poor drug delivery of CNS drugs. 15 April 2015
  • Movement Disorders Volume 30 Issue 4 Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label resultsLCIG's safety profile consisted primarily of AEs associated with the device/procedure, l-dopa/carbidopa, and advanced PD. LCIG was generally well tolerated and demonstrated clinically significant improvements in motor function, daily activities, and HRQoL sustained over 54 weeks. 15 April 2015
  • Brain scan EuroInf: A multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's diseaseBased on this open-label, nonrandomized, comparative study, authors report that, in advanced Parkinson's patients, both IJLI and Apo infusion therapy appear to provide a robust improvement in motor symptoms, motor complications, quality-of-life, and some NMS. Controlled, randomized studies are required. 15 April 2015
  • Movement Disorders Volume 30 Issue 5 Entacapone and Prostate Cancer Risk in Patients With Parkinson's DiseaseUse of entacapone with l-dopa/dopa decarboxylase inhibitor caused no increased risk of prostate cancer incidence (hazard ratio [HR]: 1.05; 95% confidence interval: 0.76-1.44) or mortality (0.93; 0.43-1.98). The HR for cumulative entacapone use of >360 days versus never-use was 0.82 (0.56-1.18) for prostate cancer incidence and 1.27 (0.60-2.72) for prostate cancer mortality. 15 April 2015
  • Neuroscience Volume 290 Nitrosative and cognitive effects of chronic L-DOPA administration in rats with intra-nigral 6-OHDA lesionStudy results show that chronic L-DOPA administration in rats with intra-nigral 6-OHDA-lesion caused significant increases in SWM deficit, nitrite levels and the immunoreactivity of 3-NT, iNOS and GFAP in the nigro-striatal-cortical pathway. These facts suggest that as L-DOPA can induce NS in rats with dopaminergic intra-nigral lesion, it could play a key role in the impairment of the SWM, and thus can be considered as a toxic mechanism that induces cognitive deficit in PD patients. 02 April 2015
  • Movement Disorders Volume 30 Issue 9 Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's diseaseAlthough the open-label study design and the greater number of rescue doses during the DM-1992 arm call for caution in interpreting the results, the elevated predose plasma l-dopa concentration (12 h after DM-1992 administration) lends objective support to our findings, suggesting that phase 3 studies are warranted. 02 April 2015
  • Brain Volume 137 Issue 11 Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding studyIt can be concluded that a single dose, oral treatment with eltoprazine has beneficial antidyskinetic effects without altering normal motor responses to L-DOPA. All doses of eltoprazine were well tolerated, with no major adverse effects. Eltoprazine has a favourable risk-benefit and pharmacokinetic profile in patients with Parkinson's disease. 01 April 2015
  • xxx Neuropsychological outcome after deep brain stimulation for Parkinson diseaseConclusions: Authors found no clinically significant differences in neuropsychological outcome between GPi DBS and STN DBS. No satisfactory explanation is available for the predictive value of baseline semantic fluency for cognitive decline. 31 March 2015
  • Movement Disorders Volume 29 Issue 6 The therapeutic potential of cannabinoids for movement disordersData are insufficient to draw conclusions regarding HD, dystonia, or ataxia and nonexistent for myoclonus or RLS. Despite the widespread publicity about the medical benefits of cannabinoids, further preclinical and clinical research is needed to better characterize the pharmacological, physiological, and therapeutic effects of this class of drugs in movement disorders. 15 March 2015
Page: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [+11]